ArticleFrontiers in oncology2021

Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity.

Federico La Manna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.